Journal
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
Volume 1868, Issue 12, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bbadis.2022.166556
Keywords
Fluorofenidone; Cholestasis; Fibrosis; Erk; -Egr-1 signaling; Tgf?1; Smad pathway
Funding
- National Natural Science Foundation of China (NSFC) [81922012]
- Outstanding Youth Science Foundation of Chongqing [cstc2021jcyj- jqX0005]
- Project of Chongqing Universities Innovation/Outstanding Medical Research Group [2021cqspt01, 414Z381/4246ZO1]
Ask authors/readers for more resources
This study found that AKF-PD effectively ameliorates cholestasis and hepatic fibrosis, significantly reducing liver function indicators and bile salt levels in a mouse model. It also attenuates hepatic inflammation and fibrosis. Mechanistic analyses revealed that AKF-PD acts through multiple pathways to exert anti-inflammatory and anti-fibrotic effects.
Cholestasis is characterized by intrahepatic accumulation of bile acids (BAs), resulting in liver injury, fibrosis, and liver failure. To date, only ursodeoxycholic acid and obeticholic acid have been approved for the treatment of cholestasis. As fluorofenidone (AKF-PD) was previously reported to play significant anti-fibrotic and anti-inflammatory roles in various diseases, we investigated whether AKF-PD ameliorates cholestasis. A mouse model of cholestasis was constructed by administering a 0.1 % 3,5-diethoxycarbonyl-1,4-dihydroxychollidine (DDC) diet for 14 days. Male C57BL/6 J mice were treated with either AKF-PD or pirfenidone (PD) orally in addition to the DDC diet. Serum and liver tissues were subsequently collected and analyzed. We found that AKF-PD significantly reduced the levels of serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bile salts (TBA), as well as hepatic bile acids (BAs) levels. Hepatic histo-logical analyses demonstrated that AKF-PD markedly attenuated hepatic inflammation and fibrosis. Further mechanistic analyses revealed that AKF-PD markedly inhibited expression of Cyp7a1, an enzyme key to BAs synthesis, by increasing Fxr nuclear translocation, and decreased hepatic inflammation by attenuating Erk/-Egr-1-mediated expression of inflammatory cytokines and chemokines Tnf alpha, Il-1 beta, Il-6, Ccl2, Ccl5 and Cxcl10. Moreover, AKF-PD was found to substantially reduce liver fibrosis via inhibition of Tgf beta 1/Smad pathway in our mouse model. Here, we found that AKF-PD effectively attenuates cholestasis and hepatic fibrosis in the mouse model of DDC-induced cholestasis. As such, AKF-PD warrants further investigation as a candidate drug for treatment of cholestasis.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available